Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1837 participants
INTERVENTIONAL
2019-08-28
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Transducers of Physical Activity Consortium (MoTrPAC) - Pediatric Protocol
NCT04151199
Physical Activity Variety's Impact on Physical Activity Participation
NCT05930431
RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)
NCT06404060
Exercise Habit and M-PAC
NCT02785107
RECOVER-ENERGIZE Platform Protocol
NCT06404047
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Biological samples collected in this project undergo molecular phenotyping, including metabolomic, lipidomic, proteomic, epigenomic, transcriptomic, and genomic analyses. These assays are done at the MoTrPAC CAS.
Overall coordination of the study and analyses occurs at 4 institutions which make up the CCC and the BIC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sedentary control
The control group does not engage in any acute exercise testing protocol, but biospecimens are collected prior to and following a period of rest.
No interventions assigned to this group
Sedentary EE
Participants randomized to EE first engage in a single acute exercise test of Endurance Exerciser (on a cycle ergometer) consistent with their random assignment.
EE Training
Participants randomized to EE engage in four center-based EE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. Each week, two of the sessions occur on a cycle ergometer and two involve treadmill exercise (4 total sessions per week). During all sessions, the participant's heart rate is monitored to ensure they maintain exercise intensity at 70% of heart rate reserve (± 5%). Periodically during training sessions perceptual data from participants are recorded, which is used to track the subjective experience of participants and in interpreting adherence data.
Sedentary RE
Participants randomized to RE first engage in a single acute exercise test of Resistance Exerciser, consistent with their random assignment.
RE Training
Participants randomized to RE engage in four center-based RE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. The prescription is a 2-day split, meaning approximately half of the major muscle groups are exercised each session and each muscle group is exercised twice per week. Two sessions per week include seven exercises that focus on the hips/thighs, back and biceps, and the other two sessions per week include seven exercises that focus on the chest, shoulders, triceps, calves and abdominal muscles. The first set per muscle group is a warm-up performed at 50-70% of prescribed loads that are based on 10-repetition maximum (10RM). Three sets per exercise are then performed at 10RM intensity. Load increases when a participant can perform 12 repetitions for 2 of 3 sets of an exercise. During all sessions, heart rate is monitored and perceived exertion is recorded.
Highly Active EE
A comparison group of highly active EE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Endurance Exerciser (HAEE) participants are tested on a cycle ergometer.
No interventions assigned to this group
Highly Active RE
A comparison group of highly active RE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Resistance Exerciser (HARE) participants are tested via a bout of resistance exercise.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EE Training
Participants randomized to EE engage in four center-based EE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. Each week, two of the sessions occur on a cycle ergometer and two involve treadmill exercise (4 total sessions per week). During all sessions, the participant's heart rate is monitored to ensure they maintain exercise intensity at 70% of heart rate reserve (± 5%). Periodically during training sessions perceptual data from participants are recorded, which is used to track the subjective experience of participants and in interpreting adherence data.
RE Training
Participants randomized to RE engage in four center-based RE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. The prescription is a 2-day split, meaning approximately half of the major muscle groups are exercised each session and each muscle group is exercised twice per week. Two sessions per week include seven exercises that focus on the hips/thighs, back and biceps, and the other two sessions per week include seven exercises that focus on the chest, shoulders, triceps, calves and abdominal muscles. The first set per muscle group is a warm-up performed at 50-70% of prescribed loads that are based on 10-repetition maximum (10RM). Three sets per exercise are then performed at 10RM intensity. Load increases when a participant can perform 12 repetitions for 2 of 3 sets of an exercise. During all sessions, heart rate is monitored and perceived exertion is recorded.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to read and speak English well enough to provide informed consent and understand instructions
* Aged ≥18 y
* Body Mass Index (BMI) ≥19 to ≤35 kg/m2
* Sedentary defined as self-reporting no more than 1 day per week, lasting no more than 60 minutes, of regular (structured) EE \[e.g., brisk walking, jogging, running, cycling, elliptical, or swimming activity that results in feelings of increased heart rate, rapid breathing, and/or sweating\] or RE (resulting in muscular fatigue) in the past year
* Persons bicycling as a mode of transportation to and from work \>1 day/week etc. are not considered sedentary
* Leisure walkers are included unless they meet the heart rate, breathing, and sweating criteria noted above
* Willingness to include de-identified individual-level data at low risk of re-identification (e.g.,non-genomic data) in the MoTrPAC open-access database
* Only one member of a household can participate
* Willingness to provide informed consent to participate in the MoTrPAC Study
* Must be able to read and speak English well enough to provide informed consent and understand instructions
* Aged ≥18 y
* BMI ≥19 to ≤35 kg/m2
* Comparator Participants
* HAEE: defined as ≥240 minutes/week of ET for ≥1 year; this can include running, walking (brisk, power), cycling, elliptical, etc. which (at a minimum) results in increased heart rate, rapid breathing and sweating
* Must include cycling at least 2 days/week
* RT in the past year must be limited to ≤2 days/week of upper body RE and ≤2 muscle groups of upper body RE and ≤1 day/week of lower body RE
* HARE: defined as RT of ≥3 upper and ≥3 lower body muscle groups ≥2 times/week for ≥1 year; using a prescription sufficient to increase strength and muscle mass
* ET in the past year must be limited to ≤90 minutes/week of vigorous EE, with no limit on cycling days per week
* Potential participants are informed that use of performance enhancing drugs in the last 6 months is exclusionary
* Willingness to include de-identified individual-level data at low risk of re-identification (e.g., non-genomic data) in the MoTrPAC open-access database
Exclusion Criteria
* Treatment with any hypoglycemic agents (self-report) or A1c \>6.4% (screening test; may reassess once if 6.5-6.7%)
* Fasting glucose \>125 mg/dL (screening test; may reassess once)
* Use of hypoglycemic drugs for non-diabetic reasons (self-report)
* Abnormal bleeding or coagulopathy (self-report)
* History of a bleeding disorder or clotting abnormality
* Thyroid disease (screening test)
* Thyroid Stimulating Hormone (TSH) value \>5.9 IU/mL
* Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting
* Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment
* Pulmonary (self-report)
* Clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
* Metabolic bone disease (self-report)
* History of non-traumatic fracture from a standing height or less
* Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen
* Estrogens, progestins (self-report)
* Supplemental, replacement or therapeutic use of estrogens or progestins within the last 6 months, other than birth control or to control menopausal symptoms
* Pregnancy (screening test) and pregnancy-related conditions (self-report)
* Pregnant - pregnancy test performed on day of DXA scan in women of child-bearing potential
* Post-partum during the last 12 months
* Lactating during the last 12 months
* Planning to become pregnant during the participation period
* Elevated blood pressure readings (screening test)
* Resting Systolic Blood Pressure (SBP) ≥150 mmHg or Resting Diastolic Blood Pressure (DBP) ≥95 mmHg
* Reassessment of BP during screening will be allowed to ensure rested values are repeatable
* Cardiovascular (self-report, screening test, and clinician judgement)
* Congestive heart failure, coronary artery disease, significant valvular disease, congenital heart disease, serious arrhythmia, stroke, or symptomatic peripheral artery disease (self-report, screening test)
* Specific criteria used to determine whether a volunteer can undergo the screening CPET follow the American Heart Association (AHA) Criteria \[54\]
* Inability to complete the CPET
* Reassessment of the CPET may be allowed under some circumstances (e.g., test was not a maximal effort)
* Abnormal blood lipid profile (screening test)
* Fasting triglycerides \>500 mg/dL
* Low-density lipoprotein cholesterol (LDL-C) \>190mg/dL
* Cancer (self-report)
* History of cancer treatment (other than non-melanoma skin cancer) and not "cancer-free" for at least 2 years
* Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months
* Chronic active or latent infection (self-report)
* Active or latent infections requiring chronic antibiotic or anti-viral treatment
* Chronic active infection whether on chronic antimicrobials or not
* Human Immunodeficiency Virus
* Active hepatitis B or C undergoing antiviral therapy
* Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded
* Liver enzyme tests (Alanine transaminase, Aspartate transaminase) (screening test)
* \>2 times the laboratory upper limit of normal
* Reassessment during screening may be allowed under some conditions (e.g., recent use of acetaminophen)
* Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting
* Chronic renal insufficiency (screening test)
* Estimated glomerular filtration rate \<60 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation
* Reassessment may be allowed under some conditions (e.g., questionable hydration status or other acute renal insult)
* Hematocrit (screening test)
* Hematocrit \>3 points outside of the local normal laboratory ranges for women and men
* Reassessment may be allowed under certain conditions
* Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting
* Individuals with known thalassemia trait may be included (despite having \>3 points outside of the local normal laboratory ranges), upon approval from their PCP or a hematologist
* Blood donation (self-report)
* Whole blood donation in the last 3 months or plans for blood donation during the entire protocol period
* Platelet or plasma donation in the last week or plans for platelet or plasma donation during the entire protocol period
* Autoimmune disorders (self-report)
* Individuals receiving any active treatment (including monoclonal antibodies) within the last 6 months
* Alcohol consumption (self-report)
* More than 7 drinks per week for women
* More than 14 drinks per week for men
* History of binge drinking (≥5 drinks for males or ≥4 drinks for females in a 2-hour period more than once per month)
* Tobacco (self-report)
* Current smokers: any tobacco or e-cigarette/e-nicotine products
* Former smokers:
* Stopped smoking \<10 years at time of screening for those with a ≥20 pack-year smoking history
* Stopped smoking \<5 years at time of screening for those with a \<20 pack-year smoking history
* Marijuana (self-report)
* Self-reported use ≥3 days/week in any form
* Shift workers (self-report)
* Night shift work in the last 6 months
* Planning night shift work during the study period
* Cognitive status (screening)
* Unable to give consent to participate in and safely complete the protocol, as based on the judgement of the local investigator
* Psychiatric illness (self-report and screening test)
* Hospitalization for any psychiatric condition within one year (self-report)
* Center for Epidemiological Studies-Depression Scale (CESD) score ≥16 \[55\] (screening test)
* Weight change (self-report)
* Weight change (intentional or not) over the last 6 months of \>5% of body weight
* Plan to lose or gain weight during the study
* Lidocaine or other local anesthetic (self-report)
* Known allergy to lidocaine or other local anesthetic
* COVID-19 infection
* Hospitalization for COVID-19 infection in the past 12 months
* Individuals who tested positive for COVID-19 but were not hospitalized must be symptom-free at least 14 days
* Other (clinician judgement)
* Genetic metabolic disorders that could effect metabolomic results (e.g.,phenylketonuria)
* Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric. metabolic, or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol
* Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol
EXCLUSIONS FOR MEDICATION USE
* Continuous use for 7 days or more of a new drug (prescription or over-the-counter; additional guidance in the MOP) in the last 3 months; eye and ear drops are allowed regardless of when they were started
* Dose change for any chronic-use drug in the last 3 months; changes in eye and ear drops are allowed
* Cardiovascular
* Beta blockers and centrally acting anti-hypertensive drugs
* Anticoagulants
* Antiarrhythmic drugs
* Antiplatelet drugs (other than aspirin ≤100 mg/day)
* Psychiatric drugs
* Chronic use of medium or long-acting sedatives and hypnotics including all benzodiazepines; (short-acting non-benzodiazepine sedative-hypnotics are allowed)
* Mood stabilizers
* Antiepileptic drugs
* Stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs
* Anti-psychotic drugs
* Pulmonary, inflammation
* Chronic oral steroids; inhaled steroids are allowed
* Burst/taper oral steroids more than once in the last 12 months; inhaled steroids are allowed
* B2-agonists
* allowed if on stable dose at least 3 months
* Genitourinary
* 5-alpha reductase inhibitors
* Daily phosphodiesterase type 5 inhibitor use
* Hormonal
* Androgenic anabolic steroids
* Anti-estrogens, anti-androgens
* Estrogens and/or progestins used for reasons other than birth control or menopause
* Growth hormone, insulin like growth factor-I, growth hormone releasing hormone
* Any drugs used to treat diabetes mellitus or to lower blood glucose
* Metformin for any indication
* Any drugs used specifically to induce weight loss
* Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise-induced muscle hypertrophy
* Pain/inflammation
* Narcotics and narcotic receptor agonists
* Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen
* Muscle relaxants ≥3 days per week
* Oral/sublingual cannabidiol or similar in any formulation
* Other
* Chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc) for any reason
* High-potency topical steroids if ≥10% of surface area using rule of 9s
* Continuous/chronic use of antibiotics or other anti-infectives for treatment or prevention
* Monoclonal antibodies
* Anti-rejection medications/immune suppressants
* Any other medications that, in the opinion of local clinicians, would negatively impact or mitigate full participation and completion
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Stanford University
OTHER
Broad Institute of MIT and Harvard
OTHER
Duke University
OTHER
Emory University
OTHER
Icahn School of Medicine at Mount Sinai
OTHER
Pacific Northwest National Laboratory
FED
University of Michigan
OTHER
Wake Forest University
OTHER
University of Vermont
OTHER
National Institutes of Health (NIH)
NIH
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Mayo Clinic
OTHER
Wake Forest University Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mike E Miller, PhD
Role: PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
University of Colorado Denver
Denver, Colorado, United States
Florida Hospital / Advent Health
Orlando, Florida, United States
Ball State University
Muncie, Indiana, United States
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Duke University Medical Center
Durham, North Carolina, United States
East Carolina University
Greenville, North Carolina, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
University of Texas Medical Branch - Galveston
Galveston, Texas, United States
University of Texas Health Science Center, San Antonio
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
MoTrPAC Study Group; Jakicic JM, Kohrt WM, Houmard JA, Miller ME, Radom-Aizik S, Rasmussen BB, Ravussin E, Serra M, Stowe CL, Trappe S, Abouassi H, Adkins JN, Alekel DL, Ashley E, Bamman MM, Bergman BC, Bessesen DH, Broskey NT, Buford TW, Burant CF, Chen H, Christle JW, Clish CB, Coen PM, Collier D, Collins KA, Cooper DM, Cortes T, Cutter GR, Dubis G, Fernandez FM, Firnhaber J, Forman DE, Gaul DA, Gay N, Gerszten RE, Goodpaster BH, Gritsenko MA, Haddad F, Huffman KM, Ilkayeva O, Jankowski CM, Jin C, Johannsen NM, Johnson J, Kelly L, Kershaw E, Kraus WE, Laughlin M, Lester B, Lindholm ME, Lowe A, Lu CJ, McGowan J, Melanson EL, Montgomery S, Moore SG, Moreau KL, Muehlbauer M, Musi N, Nair VD, Newgard CB, Newman AB, Nicklas B, Nindl BC, Ormond K, Piehowski PD, Qian WJ, Rankinen T, Rejeski WJ, Robbins J, Rogers RJ, Rooney JL, Rushing S, Sanford JA, Schauer IE, Schwartz RS, Sealfon SC, Slentz C, Sloan R, Smith KS, Snyder M, Spahn J, Sparks LM, Stefanovic-Racic M, Tanner CJ, Thalacker-Mercer A, Tracy R, Trappe TA, Volpi E, Walsh MJ, Wheeler MT, Willis L. Molecular Transducers of Physical Activity Consortium (MoTrPAC): human studies design and protocol. J Appl Physiol (1985). 2024 Sep 1;137(3):473-493. doi: 10.1152/japplphysiol.00102.2024. Epub 2024 Apr 18.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00097219
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.